Media stories about Progenics Pharmaceuticals (NASDAQ:PGNX) have been trending somewhat positive recently, Accern Sentiment reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 45.9066592402204 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
A number of brokerages recently issued reports on PGNX. ValuEngine upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 7th. Zacks Investment Research upgraded shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research note on Thursday, January 4th. BidaskClub upgraded shares of Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 14th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $15.00 price target on shares of Progenics Pharmaceuticals in a research note on Wednesday, January 17th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus price target of $12.35.
Progenics Pharmaceuticals (PGNX) opened at $5.84 on Thursday. The stock has a market cap of $410.38, a PE ratio of -7.39 and a beta of 3.40. Progenics Pharmaceuticals has a one year low of $4.60 and a one year high of $11.72. The company has a debt-to-equity ratio of 0.80, a current ratio of 7.86 and a quick ratio of 7.86.
Progenics Pharmaceuticals, Inc is engaged in developing medicines and other products for targeting and treating cancer. The Company’s pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools.
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.